Want to see AU:IIQ full AI Analyst Report?

Inoviq Ltd (IIQ) Price & Analysis

6 Followers

IIQ Stock Chart & Stats

AU$0.40

AU$0.02(3.09%)

At close: Jan 09 4:00 PM EST

AU$0.40

AU$0.02(3.09%)

Day’s Range― - ―

52-Week RangeAU$0.25 - AU$0.57

Previous CloseN/A

Volume76.26K

Average Volume (3M)196.06K

Market Cap

AU$38.01M

Enterprise ValueAU$30.50M

Total Cash (Recent Filing)AU$13.80M

Total Debt (Recent Filing)AU$270.31K

Price to Earnings (P/E)―

Beta0.10

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding140,775,450

10 Day Avg. Volume262,451

30 Day Avg. Volume196,057

Financial Highlights & Ratios

PEG Ratio0.49

Price to Book (P/B)2.46

Price to Sales (P/S)22.67

P/FCF Ratio-8.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)AU$1.65M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetA very low debt-to-equity ratio (0.0225) gives Inoviq durable financial flexibility to fund R&D, partnerships or product rollouts without high interest burdens. This reduces solvency risk and preserves strategic optionality while the business scales toward commercialization.

Exosome-focused Diagnostics PlatformA platform focus on exosome-based diagnostics and cancer detection positions the company in a structural growth niche in life sciences. Platform technologies can drive recurring product, service and partnership revenue and create defensible differentiation if translated into validated assays.

Diversified Commercialisation ModelA multi-channel revenue strategy (research product sales, diagnostic test commercialization, and collaboration/licensing) provides durable monetization options. This diversification can smooth revenue as product adoption, partner milestones and royalties materialize over time.

Bears Say

Declining Revenue TrendA 17.2% revenue decline signals weakening product or service uptake and raises concerns about market traction. Over a multi-month horizon, continued top-line contraction undermines the company’s ability to fund development internally and compromises scaling of commercial operations.

Sustained Negative ProfitabilityPersistently negative gross, EBIT and net margins indicate the business is not currently capturing sufficient value or controlling costs. Structural unprofitability reduces retained capital for reinvestment, increases reliance on external funding, and challenges long-term sustainability.

Negative Operating And Free Cash FlowNegative operating and free cash flows create ongoing liquidity pressure despite low debt. Over 2–6 months this forces reliance on financing or dilutive capital raises, limits the ability to invest in commercialisation, and increases execution risk for product launches.

Inoviq Ltd News

INOVIQ boosts EXO-OC accuracy but halts flawed ovarian cancer study

The latest update is out from Inoviq Ltd ( ($AU:IIQ) ). INOVIQ has enhanced the algorithm underpinning its...

4d ago

Inoviq Seeks Trading Halt Ahead of Key EXO-OC Clinical Study Results

Inoviq Ltd ( ($AU:IIQ) ) has provided an update. Inoviq Ltd, an ASX-listed medical diagnostics company focused on...

6d ago

Inoviq Options Lapse Removes 1.1 Million Potential Shares

Inoviq Ltd ( ($AU:IIQ) ) just unveiled an update. Inoviq Ltd has notified the market that 1,100,000 options,...

9d ago

INOVIQ posts strong ovarian cancer data for off-the-shelf CAR-exosome therapy

Inoviq Ltd ( ($AU:IIQ) ) has provided an announcement. INOVIQ reported positive in vitro proof-of-concept data showing its...

10d ago

Inoviq links share price jump to research note as key EXO-OC study nears milestone

The latest announcement is out from Inoviq Ltd ( ($AU:IIQ) ). Inoviq has responded to an ASX price...

18d ago

INOVIQ Director Peter Gunzburg Lifts Indirect Shareholding

Inoviq Ltd ( ($AU:IIQ) ) has issued an update. INOVIQ Limited has reported a change in the indirect...

1M ago

Inoviq Advances Ovarian Cancer Test and CAR-Exosome Pipeline as Cash Reserves Support Growth

Inoviq Ltd ( ($AU:IIQ) ) has issued an announcement. Inoviq reported progress across its exosome-based oncology portfolio, with...

2M ago

Inoviq Director Max Johnston Increases Indirect Shareholding via On-Market Purchase

An announcement from Inoviq Ltd ( ($AU:IIQ) ) is now available. Inoviq director Max Johnston has increased his...

3M ago

INOVIQ Director Mary Harney Buys 60,000 Shares on Market

An update from Inoviq Ltd ( ($AU:IIQ) ) is now available. INOVIQ director Mary Harney has increased her...

3M ago

Inoviq director increases indirect shareholding through on-market purchase

Inoviq Ltd ( ($AU:IIQ) ) has issued an update. Inoviq Limited has disclosed a change in director Peter...

4M ago

IIQ FAQ

What was Inoviq Ltd’s price range in the past 12 months?

Inoviq Ltd lowest share price was AU$0.24 and its highest was AU$0.56 in the past 12 months.

What is Inoviq Ltd’s market cap?

Inoviq Ltd’s market cap is AU$38.01M.

When is Inoviq Ltd’s upcoming earnings report date?

Inoviq Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 59 days.

How were Inoviq Ltd’s earnings last quarter?

Inoviq Ltd released its earnings results on Feb 20, 2026. The company reported -AU$0.032 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.032.

Is Inoviq Ltd overvalued?

According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Inoviq Ltd pay dividends?

Inoviq Ltd does not currently pay dividends.

What is Inoviq Ltd’s EPS estimate?

Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Inoviq Ltd have?

Inoviq Ltd has 140,775,450 shares outstanding.

What happened to Inoviq Ltd’s price movement after its last earnings report?

Inoviq Ltd reported an EPS of -AU$0.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.899%.

Which hedge fund is a major shareholder of Inoviq Ltd?

Currently, no hedge funds are holding shares in AU:IIQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Inoviq Ltd Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.14%

Trailing 12-Months

Asset Growth

15.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Inoviq Ltd

INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.